1	[Settlement of Lawsuit - Allergan Finance, LLC and Allergan Limited - City to Receive \$12,916,274 Over 5 Years]
2	
3	Ordinance authorizing settlement of the lawsuit filed by the City and County of San
4	Francisco and the People of the State of California against Allergan Finance, LLC (f/k/a
5	Actavis, Inc., which, in turn, was f/k/a Watson Pharmaceuticals, Inc.) and Allergan
6	Limited (f/k/a Allergan plc, which, in turn, was f/k/a Actavis plc) for \$12,916,274 (the City
7	to be paid \$10,156,889 over 5 years, the City's outside counsel to be paid \$1,585,179,
8	and the City Attorney's Office to be paid \$1,174,206); directing the Controller to allocate
9	funds to the City Attorney's Office as provided in the settlement agreement; the lawsuit
10	was filed on December 18, 2018, in the United States District Court for the Northern
11	District of California, Case No. 3:18-cv-7591-CRB-JSC; entitled The City and County of
12	San Francisco and the People of the State of California v. Purdue Pharma L.P., Richard
13	S. Sackler, Jonathan D. Sackler, Mortimer D.A. Sackler, Kathe A. Sackler, Ilene Sackler
14	Lefcourt, Beverly Sackler, Theresa Sackler, David A. Sackler, Trust for the Benefit of
15	Members of the Raymond Sackler Family, Rhodes Pharmaceuticals L.P., Cephalon,
16	Inc., Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., Endo
17	International Plc, Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Janssen
18	Pharmaceuticals, Inc., Insys Therapeutics, Inc., Mallinckrodt Plc, Mallinckrodt LLC,
19	Allergan Plc f/k/a Actavis Plc, Watson Pharmaceuticals, Inc. n/k/a Actavis, Inc., Watson
20	Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc. f/k/a Watson Pharma, Inc.,
21	AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation; the
22	lawsuit involves allegations that the Allergan defendants created a public nuisance and
23	violated the Unfair Competition Law by falsely and misleadingly marketing opioids as
24	safer than they actually are and distributing increasingly large volumes of opioids in
25	and around San Francisco despite knowledge of the growing epidemic caused by

opioid misuse, and by failing to prevent and report suspicious opioid orders as required by state and federal law.

Be it ordained by the People of the City and County of San Francisco:

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

1

2

3

Section 1. Pursuant to Charter Section 6.102(5), the Board of Supervisors hereby authorizes the City Attorney to settle the action entitled The City and County of San Francisco and the People of the State of California v. Purdue Pharma L.P., Richard S. Sackler, Jonathan D. Sackler, Mortimer D.A. Sackler, Kathe A. Sackler, Ilene Sackler Lefcourt, Beverly Sackler, Theresa Sackler, David A. Sackler, Trust for the Benefit of Members of the Raymond Sackler Family, Rhodes Pharmaceuticals L.P., Cephalon, Inc., Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., Endo International Plc, Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Insys Therapeutics, Inc., Mallinckrodt Plc, Mallinckrodt LLC, Allergan Plc f/k/a Actavis Plc, Watson Pharmaceuticals, Inc. n/k/a Actavis, Inc., Watson Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc. f/k/a Watson Pharma, Inc., AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation, the United States District Court for the Northern District of California, Case No. 3:18-cv-7591-CRB-JSC by the payment of \$12,916,274 (the City to be paid \$10,156,889 over 5 years, the City's outside counsel to be paid \$1,585,179, and the City Attorney's Office to be paid \$1,174,206) by Allergan Finance, LLC (f/k/a Actavis, Inc., which, in turn, was f/k/a Watson Pharmaceuticals, Inc.) and Allergan Limited (f/k/a Allergan plc, which, in turn, was f/k/a Actavis plc). The lawsuit involves allegations that the Allergan defendants created a public nuisance and violated the Unfair Competition Law by falsely and misleadingly marketing opioids as safer than they actually are and distributing increasingly large volumes of opioids in and around San Francisco despite knowledge of the growing epidemic caused by

1	opioid misuse, and by failing to prevent and report suspicious opioid orders as required by
2	state and federal law.
3	Section 2. The above-named action was filed in the United States District Court for the
4	Northern District of California on December 18, 2018, and the following parties were named in
5	the lawsuit: The City and County of San Francisco and the People of the State of California,
6	as plaintiffs; Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company, Inc.;
7	Rhodes Pharmaceuticals L.P.; Richard S. Sackler; Jonathan D. Sackler; Mortimer D.A.
8	Sackler, Kathe A. Sackler; Ilene Sackler Lefcourt; Beverly Sackler; Theresa Sackler; David A.
9	Sackler; Trust for the Benefit of the Raymond Sackler Family; Allergan Plc f/k/a Actavis Plc;
10	Allergan Finance, LLC f/k/a Actavis, Inc. f/k/a Watson Pharmaceuticals, Inc.; Allergan Sales,
11	LLC; Allergan USA, Inc.; Watson Laboratories, Inc.; Warner Chilcott Company, LLC; Actavis
12	Pharma, Inc. f/k/a Watson Pharma, Inc.; Actavis South Atlantic LLC; Actavis Elizabeth LLC;
13	Actavis Mid Atlantic LLC; Actavis Totowa LLC; Actavis LLC; Actavis Kadian LLC; Actavis
14	Laboratories UT, Inc. f/k/a Watson Laboratories, IncSalt Lake City; Actavis Laboratories FL,
15	Inc. f/k/a Watson Laboratories, IncFlorida; Teva Pharmaceuticals USA, Inc.; Teva
16	Pharmaceutical Industries Ltd.; Cephalon, Inc.; Johnson & Johnson; Janssen
17	Pharmaceuticals, Inc.; Noramco, Inc.; Ortho-Mcneil-Janssen Pharmaceuticals, Inc.; Janssen
18	Pharmaceutica, Inc.; Endo Health Solutions Inc.; Endo Pharmaceuticals, Inc.; Par
19	Pharmaceuticals, Inc.; Par Pharmaceutical Companies, Inc. f/k/a Par Pharmaceutical
20	Holdings, Inc.; Endo International Plc; Insys Therapeutics, Inc.; Mallinckrodt Plc; Mallinckrodt
21	LLC; Specgx LLC; AmerisourceBergen Drug Corporation; Anda, Inc.; Cardinal Health, Inc.;
22	McKesson Corporation; and Walgreen Co. as defendants.
23	Section 3. The Controller is hereby authorized and directed to allocate the payment of

funds for the reimbursement of attorneys' fees to the City Attorney's Office in the amount

provided in the settlement agreement.

24

25

1	
2	APPROVED AS TO FORM:
3	DAVID CHIU, City Attorney
4	By: <u>/s/ Sara J. Eisenberg</u> SARA J. EISENBERG
5	Chief of Complex and Affirmative Litigation
6	n:\cpu\li2023\190034\01657178.docx
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	